Teyi Pharmaceutical Group Co.,Ltd

002728

CNE100001WK6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
7.54 ^CNY	+0.40%		+2.45%	-41.09%

02/07	Tranche Update on Teyi Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on June 12, 2024.	CI
12/06	Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3%	MT

Tranche Update on Teyi Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on June 12, 2024.

July 03, 2024 at 01:08 am IST

From June 11, 2024 to June 30, 2024, the company has repurchased 509,316 shares, representing 0.1% for CNY 4.15 million. With this, the company has completed the repurchase of 509,316 shares, representing 0.1% for CNY 4.15 million under the buyback announced on June 12, 2024.

Latest news about Teyi Pharmaceutical Group Co.,Ltd

Tranche Update on Teyi Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on June 12, 2024.	03/07	CI
Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3%	12/06	MT
Teyi Pharmaceutical Group Co.,Ltd announces an Equity Buyback for CNY 120 million worth of its shares.	11/06	CI
Teyi Pharmaceutical Group Co.,Ltd authorizes a Buyback Plan.	11/06	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023	29/03	CI
Teyi Pharmaceutical Group Co.,Ltd Proposes Final Cash Dividend for the Year 2023	09/03	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23/23/23	CI
Teyi Pharmaceutical Group Co.,Ltd announced that it has received CNY 274.999916 million in funding from AEGON-Industrial Fund Management Co. Ltd., Donghai Funds Management Co., Ltd., Caitong Fund Management Co., Ltd., Allianz Insurance Asset Management Co., Ltd., Nuode Asset Management Co., Ltd., China Great Wall Securities Co.,Ltd.	28/23/28	CI
Teyi Pharmaceutical's Hypertension Drug Passes Regulatory Evaluation	20/23/20	MT
Teyi Pharmaceutical Group Co.,Ltd(XSEC:002728) added to S&P Global BMI Index	18/23/18	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023	20/23/20	CI
Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022	18/23/18	CI
Teyi Pharmaceutical Group Co.,Ltd Propose Final Cash Dividend for 2022	27/23/27	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Teyi Pharmaceutical Proposes Guangzhou Branch	22/23/22	MT
Teyi Pharmaceutical Ties Up With Educational Institution for Anti-Cough Tablets Study	21/22/21	MT
China stocks end lower as COVID outbreaks cast doubts on reopening	21/22/21	RE
China stocks fall as COVID outbreaks dash hopes of eased curbs	21/22/21	RE
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments	29/22/29	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022	30/22/30	CI

Chart Teyi Pharmaceutical Group Co.,Ltd

Duration

Period

More charts

Company Profile

TEYI PHARMACEUTICAL GROUP CO., LTD, formerly Guangdong Taicheng Pharmaceutical Co., Ltd., is principally engaged in the production and sale of pharmaceuticals. The Company primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The Company's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Sector

Pharmaceuticals

Calendar

19/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Teyi Pharmaceutical Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.54

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEYI PHARMACEUTICAL GROUP CO.,LTD	-41.09%	53Cr
ELI LILLY AND COMPANY	+55.35%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.10%	36TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals

Teyi Pharmaceutical Group Co.,Ltd

Equities

002728

CNE100001WK6

Pharmaceuticals

Tranche Update on Teyi Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on June 12, 2024.

Latest news about Teyi Pharmaceutical Group Co.,Ltd

Chart Teyi Pharmaceutical Group Co.,Ltd

Company Profile

Income Statement Evolution

Ratings for Teyi Pharmaceutical Group Co.,Ltd

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals